NasdaqGS:ELVNPharmaceuticals
Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress
Enliven Therapeutics (ELVN) is back in focus after Chief Scientific Officer Joseph P. Lyssikatos sold 20,000 shares, following encouraging early ELVN-001 leukemia trial data and as the company prepares for potential later stage studies.
See our latest analysis for Enliven Therapeutics.
At a latest share price of $28.17, Enliven’s recent 1 month share price return of 81.27% and 90 day share price return of 48.19% suggest strong momentum. The 1 year total shareholder return of 28.63% points to...